Compare Ascendis Pharma A/S (ASND) vs Badger Meter Inc (BMI) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

Badger Meter (BMI) trades at $144.18, down 0.54% today, with a bullish technical outlook supported by moving averages and strong ADX readings. The company maintains solid profitability with 14.56% net margin and 19.6% ROE, though recent earnings misses and a securities class action lawsuit create near-term uncertainty. Revenue declined to $897M in 2026 from $917M in 2025, while cash flow improved to positive $74M.

BMI presents a mixed investment case with strong fundamentals offset by legal risks. The stock trades near analyst consensus target of $144.80, offering limited upside. While operational metrics remain healthy, the pending class action and recent earnings volatility warrant caution. Institutional sentiment leans neutral with 55.55% hold ratings, suggesting investors await legal resolution and earnings stabilization.